Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Sarcoma 2 Triple Negative Breast Neoplasms 1 Sarcoma, Ewing 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasm Metastasis 1 Her-2 Negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1 Advanced Solid Tumors 1

Interventions

Cyclophosphamide 8 fludarabine 6 cabozantinib 5 Temozolomide 4 Doxorubicin 4 Zoledronic Acid 3 X-Rays 3 Vincristine 3 Methotrexate 3 Ifosfamide 3 Gemcitabine 3 Cisplatin 3 irinotecan sucrosofate 2 atezolizumab 2 Surgical Procedures, Operative 2 Sunitinib 2 Specimen Handling 2 Radiosurgery 2 Phantoms, Imaging 2 Mesna 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2 Eflornithine 2 Disulfiram 2 Biopsy 2 vactosertib 1 trilaciclib 1 trametinib 1 talazoparib 1 surufatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Osteosarcoma × fluzoparib × Clear all

NCT06074692 2023-10-31

PRIMA

Ruijin Hospital

Phase 2 Recruiting

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡